A Phase 1 interventional study of 5 Methoxy N,N Dimethyltryptamine in Healthy Volunteers, sponsored by GH Research Ireland Limited. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by GH Research Ireland Limited · Phase 1, Interventional, and Treatment
The Sponsor elected to stop the trial after Part 1 and 2, having determined the scientific objective was met with sufficient data to select doses for future trials. Not driven by safety, tolerability, or recruitment; all subjects completed the trial.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label Phase 1 trial in healthy subjects designed to characterize the pharmacokinetic (PK) profile, pharmacodynamics, and safety and tolerability of GH001 (mebufotenin) delivered via the GH001 Aerosol Delivery System (ADS).
The trial is conducted in three parts. In Part 1, subjects receive a single dose of GH001 via the ADS. In Part 2, subjects receive GH001 via both the ADS and the Volcano Medic 2 Vaporization System in a crossover design, to estimate the relative bioavailability of mebufotenin between the two delivery systems. In Part 3, subjects receive a single-day individualized dosing regimen (IDR) of GH001 via the ADS, in which up to three increasing doses are given at approximately 1-hour intervals.
The primary objectives are to determine the serum PK profile of mebufotenin and its metabolites and to evaluate the safety and tolerability of GH001 across these parts. Secondary objectives include characterizing the pharmacodynamic profile, as assessed by its psychoactive effects (PsE) and effects on cognitive performance, and estimating the time for the maximum serum concentration (Cmax) to decline by 50% and 90% (tCmax/2 and tCmax/10).
Part 3 of this trial was not initiated. The trial was terminated after Part 2.
GH Research Ireland Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single inhaled dose of 6 mg GH001 administered via a proprietary aerosol delivery device in eight subjects.
Drug: 5 Methoxy N,N Dimethyltryptamine
A single inhaled dose of 12 mg GH001 administered via a proprietary aerosol delivery device in eight subjects.
Drug: 5 Methoxy N,N Dimethyltryptamine
A single inhaled dose of GH001 administered via a proprietary aerosol delivery device in eight subjects.
Drug: 5 Methoxy N,N Dimethyltryptamine
A single inhaled intermediate dose of GH001 administered via a proprietary aerosol delivery device in eight subjects (optional cohort dependent on study safety group \[SSG\] review of PK, PD, and safety data from Cohorts A, B, and C).
Drug: 5 Methoxy N,N Dimethyltryptamine
A single inhaled intermediate dose of GH001 administered via a proprietary aerosol delivery device in eight subjects (optional cohort dependent on study safety group \[SSG\] review of PK, PD, and safety data from Cohorts A, B, and C).
Drug: 5 Methoxy N,N Dimethyltryptamine
A single inhaled intermediate dose of GH001 administered via a proprietary aerosol delivery device in eight subjects (optional cohort dependent on study safety group \[SSG\] review of PK, PD, and safety data from Cohorts D and E).
Drug: 5 Methoxy N,N Dimethyltryptamine
A single inhaled intermediate dose of GH001 administered via a proprietary aerosol delivery device in eight subjects (optional cohort dependent on study safety group \[SSG\] review of PK, PD, and safety data from Cohorts D and E).
Drug: 5 Methoxy N,N Dimethyltryptamine
A single-sequence crossover cohort of 12 subjects. Each subject receives a single inhaled dose of 6 mg GH001 administered via the Volcano Medic 2 Vaporization System in Treatment Period 1, followed by a single inhaled dose of 6 mg GH001 administered via a proprietary aerosol delivery device in Treatment Period 2, with 14 days between the dosing day of each treatment period.
Drug: 5 Methoxy N,N Dimethyltryptamine
A randomized, two-sequence crossover cohort of up to 16 subjects. Each subject is randomly assigned to a device administration sequence and receives a single inhaled dose of 6 mg GH001 via the Volcano Medic 2 Vaporization System and a single inhaled dose of GH001 via a proprietary aerosol delivery device across two treatment periods, with 14 days between the dosing day of each treatment period. The dose administered via the proprietary aerosol delivery device is determined by the study safety group (SSG) to achieve systemic exposure comparable to 6 mg GH001 administered via the Volcano Medic 2 Vaporization System.
Drug: 5 Methoxy N,N Dimethyltryptamine
An individualized dosing regimen (IDR) of GH001 administered via a proprietary aerosol delivery device on a single day in 12 subjects. Up to three escalating doses are administered at approximately 1-hour intervals. The second and third doses are administered only if a peak experience was not achieved after the previous dose, the previous dose was satisfactorily tolerated, any psychoactive effects of the previous dose have substantially subsided, and vital signs and FEV1 are acceptable. This cohort was not initiated. The trial was terminated after Part 2.
Drug: 5 Methoxy N,N Dimethyltryptamine
An optional individualized dosing regimen (IDR) cohort of 12 subjects, identical in design to Cohort J, administered via a proprietary aerosol delivery device. Enrolled only if safety, PK, and PD data from Cohort J indicate further exploration is needed (dependent on study safety group \[SSG\] review). This cohort was not initiated. The trial was terminated after Part 2.
Drug: 5 Methoxy N,N Dimethyltryptamine
GH001 administered via inhalation
Also known as: Mebufotenin, 5-MeO-DMT, GH001
Serum PK parameters of mebufotenin - maximum observed concentration (Cmax)
For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.
Time frame: Up to 6 hours
Serum PK parameters of mebufotenin - time of maximum observed concentration (Tmax)
For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.
Time frame: Up to 6 hours
Serum PK parameters of mebufotenin - terminal elimination half-life (t1/2)
For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.
Time frame: Up to 6 hours
Serum PK parameters of mebufotenin - area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUClast)
For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.
Time frame: Up to 6 hours
Serum PK parameters of mebufotenin - area under the serum concentration-time curve extrapolated to infinity (AUCinf)
For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.
Time frame: Up to 6 hours
Serum PK parameters of mebufotenin - partial area under the curve between t1 and t2 (AUCt1-t2)
For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.
Time frame: Up to 6 hours
Serum PK parameters of mebufotenin - terminal elimination rate constant (λz)
For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.
Time frame: Up to 6 hours
Serum PK parameters of mebufotenin - apparent total body clearance (CL/F)
For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.
Time frame: Up to 6 hours
Serum PK parameters of mebufotenin - apparent volume of distribution (up to bioavailability) after extravascular administration (Vz/F)
For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.
Time frame: Up to 6 hours
Serum PK parameters of mebufotenin - Cmax/AUCinf
For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.
Time frame: Up to 6 hours
Safety and tolerability: incidence of treatment-emergent adverse events
Adverse events reported in the study and coded by MedDRA.
Time frame: Up to 7 days
Safety and tolerability: clinically significant changes from baseline in electrocardiogram (ECG), vital signs, spirometry and safety laboratory assessments
Percentage of subjects with clinically significant changes\* from baseline in ECG (heart rate, RR, QT, PR, and QRS intervals, and QTcF). Percentage of subjects with clinically significant changes\* from baseline in vital signs (systolic and diastolic blood pressure, respiration rate, heart rate, peripheral oxygen saturation, body temperature). Percentage of subjects with clinically significant changes\* from baseline in spirometry (forced expiratory volume in 1 second \[FEV1\] and forced vital capacity \[FVC\]). Percentage of subjects with clinically significant changes\* from baseline in safety laboratory assessments (hematology, biochemistry, and urinalysis). \*Clinically significant changes as determined by the principal investigator
Time frame: Up to 7 days
Safety and tolerability: assessment of sedation (Modified Observer's Assessment of Alertness and Sedation [MOAA/S]) following each dose and as part of the discharge evaluation on Day 0
The MOAA/S will be completed before and after GH001 dosing. Scored from 0 (deep sedation) to 5 (alert).
Time frame: Postdose, up to discharge on dosing day (Day 0)
Safety and tolerability: change from baseline in Clinician Administered Dissociative States Scale (CADSS)
The CADSS comprises 19 subjective items, ranging from 0 'not at all' to 4 'extremely'. Summed together, these subscales form a total dissociative score. Combined score ranges from 0 to 76.
Time frame: From baseline up to 7 days
Safety and tolerability: assessment of subject discharge readiness at discharge on Day 0
Assessment of Discharge Readiness on the administration day by the principal investigator, using the Clinical Assessment of Discharge Readiness (CADR).
Time frame: Postdose, at discharge on dosing day (Day 0)
Safety and tolerability: Columbia-Suicide Severity Rating Scale (C-SSRS) categorization.
A detailed questionnaire assessing both suicidal behaviour and suicidal ideation.
Time frame: Up to 7 days
Safety and tolerability: Change from baseline in Brief Psychiatric Rating Scale (BPRS).
A scale to measure psychiatric symptoms. Each symptom is rated 1-7 and a total of 18 symptoms are scored. Combined score ranges from 18 to 126 and a higher score means a worse outcome.
Time frame: From baseline up to 7 days
Estimate of the relative bioavailability for Cmax, AUClast, AUCinf, and AUCt1-t2 of mebufotenin
Estimate of the relative bioavailability between the GH001 ADS and Volcano Medic 2 Vaporization System for Cmax, AUClast, AUCinf, and AUCt1-t2 of mebufotenin
Time frame: Up to 6 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Mar 2026, 19 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Feb 2025 → Mar 2026 and completion Feb 2025 → Mar 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
The Sponsor elected to stop the trial after Part 1 and 2, having determined the scientific objective was met with sufficient data to select doses for future trials. Not driven by safety, tolerability, or recruitment; all subjects completed the trial.
The Sponsor elected to stop the trial after Part 1 and 2, having determined the scientific objective was met with sufficient data to select doses for future trials. Not driven by safety, tolerability, or recruitment; all subjects completed the trial.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methoxydimethyltryptamines
GH Research Ireland Limited